Enteroendocrine cells and lipid absorption

Current Opinion in Lipidology

Volumn 22, Issue 3, 2011, Pages 171-175

  Mellitzer, Georg ^a   Gradwohl, Gerard ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

apoB 48; CD36; enteroendocrine hormones; lipid absorption; neurogenin 3

Indexed keywords

APOLIPOPROTEIN B48; CD36 ANTIGEN; CHYLOMICRON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2; NEUROGENIN 3;

APPETITE; ARTICLE; CELL LOSS; ENTEROENDOCRINE CELL; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLYCOSYLATION; GROWTH RETARDATION; HUMAN; LIPID ABSORPTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ENTEROENDOCRINE CELLS; GASTROINTESTINAL HORMONES; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; LIPID METABOLISM;

CRICETINAE;

EID: 79957905736     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834622a2     Document Type: Article

References (46)

1. Ahlman H, Nilsson. The gut as the largest endocrine organ in the body. Ann Oncol 2001; 12 (Suppl 2):S63-S68. (Pubitemid 33069689)
2. DelValle J, Yamada T. The gut as an endocrine organ. Annu Rev Med 1990; 41:447-455. (Pubitemid 20121750)
3. Rindi G, Leiter AB, Kopin AS, et al. The "normal" endocrine cell of the gut: changing concepts and new evidences. Ann N Y Acad Sci 2004; 1014:1-12. (Pubitemid 38594786)
4. Buchan AM. Nutrient Tasting and Signalling Mechanisms in the Gut III. Endocrine cell recognition of luminal nutrients. Am J Physiol 1999; 277:G1103-G1107. (Pubitemid 30046013)
5. Dockray G. Gut endocrine secretionsand their relevanceto satiety. Curr Opin Pharmacol 2004; 4:557-560. (Pubitemid 40267868)
6. Dockray GJ. Luminal sensing in the gut: an overview. J Physiol Pharmacol 2003; 54 (Suppl 4):9-17.
7. Dockray GJ. Cholecystokinin and gut-brain signalling. Regul Pept 2009; 155:6-10.
8. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117:24-32. (Pubitemid 46048446)
9. Geraedts MC, Troost FJ, Saris WH. Gastrointestinal targets to modulate satiety and food intake. Obes Rev 2010. [Epub ahead of print]. doi: 10.1111/j.1467-789X.2010.00788.x
10. Sternini C, Anselmi L, Rozengurt E. Enteroendocrine cells: a site of 'taste' in gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes 2008; 15:73-78.
11. Murphy KG, Bloom SR. Gut hormones and the regulation of energy home-ostasis. Nature 2006; 444:854-859. (Pubitemid 46024992)
12. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 2006; 27:719-727. (Pubitemid 44936055)
13. Majumdar ID, Weber HC. Gastrointestinal regulatory peptides and their effects on fat tissue. Curr Opin Endocrinol Diabetes Obes 2010; 17:51-56.
14. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27:1496-1504. (Pubitemid 38680002)
15. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin North Am 2004; 88:897-909; x. (Pubitemid 39090344)
16. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med 2003; 163:33-40. (Pubitemid 36091598)
17. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5:150-159.
18. Taskinen MR. Diabeticdyslipidaemia: from basic research toclinical practice. Diabetologia 2003; 46:733-749.
19. Qin X, Shen H, Liu M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288:G943-G949. (Pubitemid 40563135)
20. Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of nones-terified fatty acids in humans. Diabetologia 2006; 49:452-458. (Pubitemid 43277867)
21. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49:2049-2057. (Pubitemid 44168471)
22. MeierJJ, NauckMA, PottA, et al. Glucagon-like peptide2 stimulatesglucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006; 130:44-54. (Pubitemid 43049834)
23. Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential rolefortheenteroinsularaxis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004; 53:1326-1335. (Pubitemid 38569020)
24. MellitzerG, BeucherA, Lobstein V, et al. Lossof enteroendocrinecells in mice alters lipid absorption and glucose homeostasis and impairs postnatal survival. J Clin Invest 2010; 120:1708-1721.
25. Cortina G, Smart CN, Farmer DG, et al. Enteroendocrine cell dysgenesis and malabsorption, a histopathologic and immunohistochemical characterization. Hum Pathol 2007; 38:570-580. (Pubitemid 46420343)
26. Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med 2006; 355:270-280. (Pubitemid 44079341)
27. Hsieh J, Longuet C, Maida A, et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 2009; 137:997-1005; 1005 e1-e4.
28. Coburn CT, Knapp FF Jr, Febbraio M, et al. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem 2000; 275:32523-32529.
29. Dawson DW, PearceSF, Zhong R, et al. CD36 mediatesthe In vitro inhibitory effectsofthrombospondin-1 on endothelial cells. J Cell Biol1997; 138:707-717. (Pubitemid 27349849)
30. Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993; 268:11811-11816. (Pubitemid 23168135)
31. Tandon NN, Kralisz U, Jamieson GA. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 1989; 264:7576-7583. (Pubitemid 19119175)
32. Drover VA, Ajmal M, Nassir F, et al. CD36 deficiency impairs intestinal lipid secretion and clearance of chylomicrons from the blood. J Clin Invest 2005; 115:1290-1297. (Pubitemid 40629048)
33. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010; 53:552-561.
34. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 1996; 10:342-355. (Pubitemid 26112399)
35. Holst JJ. Glucagon and glucagon-like peptides 1 and 2. Results Probl Cell Differ 50:121-135.
36. Rothenberg ME, Eilertson CD, Klein K, et al. Processing of mouse proglu-cagon by recombinant prohormone convertase 1 and immunopurified pro-hormone convertase 2 in vitro. J Biol Chem 1995; 270:10136-10146.
37. Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharma-col 2003; 81:1005-1012. (Pubitemid 38045829)
38. Orskov C, Holst JJ, Knuhtsen S, et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119:1467-1475. (Pubitemid 17170509)
39. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998; 141:179-186. (Pubitemid 28393391)
40. Hansen LH, Abrahamsen N, Nishimura E. Glucagon receptor mRNA distribu-tion in rat tissues. Peptides 1995; 16:1163-1166.
41. Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999; 96:1569-1573. (Pubitemid 29098492)
42. Svoboda M, Tastenoy M, Vertongen P, Robberecht P. Relative quantitative analysis of glucagon receptor mRNA in rattissues. Mol Cell Endocrinol 1994; 105:131-137. (Pubitemid 24313980)
43. Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 11 9:744-755.
44. Hartmann B, Harr MB, Jeppesen PB, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000; 85:2884-2888. (Pubitemid 32269168)
45. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136:3585-3596.
46. Tavares W, Drucker DJ, Brubaker PL Enzymatic-and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 2000; 278:E134-E139. (Pubitemid 30101930)